Rocket Pharmaceuticals Inc., a late-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for treating Danon disease. The hold was removed in under three months, highlighting the FDA's efficient review process. The trial will proceed with a recalibrated dose, aligning with successful outcomes from the Phase 1 study. The study aims to support accelerated approval by evaluating the efficacy of RP-A501 through various biomarkers and clinical endpoints. A global natural history study is also running concurrently with this pivotal trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。